MARKET

EVOK

EVOK

Evoke Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.530
-0.120
-2.58%
After Hours: 4.560 +0.03 +0.66% 16:53 10/23 EDT
OPEN
4.780
PREV CLOSE
4.650
HIGH
4.780
LOW
4.510
VOLUME
98.38K
TURNOVER
--
52 WEEK HIGH
6.06
52 WEEK LOW
0.7900
MARKET CAP
117.83M
P/E (TTM)
-9.4790
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Evoke Pharma to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief Business Officer
GlobeNewswire · 09/09 13:30
New Strong Sell Stocks for August 24th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 08/24 12:27
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 11:29
Evoke Pharma EPS misses by $0.20
Evoke Pharma (NASDAQ:EVOK): Q2 GAAP EPS of -$0.28 misses by $0.20. Cash and cash equivalents of $7.99M. Press Release
seekingalpha · 08/06 18:11
Evoke Pharma Reports Second Quarter 2020 Financial Results
Preparing for commercial launch of GIMOTI™ in 4Q 2020SOLANA BEACH, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its fin
GlobeNewswire · 08/06 12:30
Evoke Pharma Initiates Commercial Manufacturing of Gimoti
Benzinga · 07/15 12:30
Evoke Pharma Initiates Commercial Manufacturing of Gimoti™
SOLANA BEACH, Calif., July 15, 2020 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.
GlobeNewswire · 07/15 12:30
Evoke Pharma Extends Cash Runway to 2Q 2021
GlobeNewswire · 07/08 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVOK. Analyze the recent business situations of Evoke Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVOK stock price target is 9.50 with a high estimate of 10.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 1.92M
% Owned: 7.39%
Shares Outstanding: 26.01M
TypeInstitutionsShares
Increased
7
345.19K
New
9
-430.90K
Decreased
1
15.54K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.74%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Co-Founder/Director
Cam Garner
Chief Executive Officer/Founder/Director
David Gonyer
Executive Vice President/Treasurer/Secretary
Matthew D'Onofrio
Other
Marilyn Carlson
Director
Todd Brady
Director
Ann Rhoads
Director
Ken Widder
Director
Kenneth Widder
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EVOK
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Evoke Pharma Inc stock information, including NASDAQ:EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.